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SYNOPSIS 
 
Short-term treatment outcomes of children starting ART in the ICU, general medical 
wards and outpatient HIV clinics at Red Cross War Memorial Children’s Hospital 
(RCWMCH): A Retrospective Cohort Study 
 
Background: Antiretroviral therapy (ART) has proven to decrease morbidity and mortality 
in HIV-infected children and improve immunologic, virologic and clinical outcomes.  As 
clinical management policies evolved, an emphasis on early infant testing was adopted 
resulting in an increasing number of children being diagnosed and commenced on therapy 
before the onset of severe disease progression.  However, a fair proportion still remain 
untested and subsequently present to hospital with advanced immunosuppression and severe 
disease.  Since the advent of the 2013 national Standard Treatment Guidelines which 
encourage expedited initiation of ART within 7 days of HIV diagnosis in all children under 
the age of 12 months and in those with advanced immunosuppression, it is likely that many 
HIV-infected children are being initiated on ART during hospitalisation in South Africa.  No 
local published data on these outcomes exist.  We assessed the short-term outcomes of 
children initiated on ART in the intensive care unit (ICU), general medical wards (GMWs) 
and outpatient HIV clinics (OHCs) at RCWMCH. 
Methods:   
Structured Literature Review 
A Pubmed search looking at outcomes of treatment naïve HIV-infected children and 
adolescents up to 19 years of age living in South Africa commenced on 1st line ART 
regimens in accordance to the national guidelines presiding at the time, over a 10 year period 
was performed.  This served to identify gaps in knowledge around paediatric ART in a South 
African context warranting further research.   
Retrospective Cohort Study 
We conducted a retrospective cohort study of HIV-infected children <13 years of age, 
commenced on first line ART between January 2008 and December 2011 at RCWMCH.  
Outcome measures included death, virologic suppression and changes in CD4 count and 
percentage.  Kaplan-Meier estimates, multivariate Cox proportional hazard ratios and logistic 
regression were used to estimate outcomes 6 months after ART initiation. 
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Results:   
Structured Literature Review 
This review identified several knowledge gaps. One of these gaps, the treatment outcomes of 
children started on ART at different service levels within tertiary health care settings was 
addressed in our retrospective cohort study and described in section C of this dissertation  
Retrospective Cohort Study 
Seven hundred and forty-nine children were included:  106 were commenced on ART in the 
ICU, 509 in the GMWs and 127 in the OHCs.  Four hundred and ninety-two (65.7%) children 
were <12 months old.  Children in the ICU and GMW cohorts were significantly younger 
than the OHC cohort (median ages: 3 and 5 months respectively vs. 22 months) and had 
lower WAZ scores (-2.48 and -2.33 respectively vs -1.14).  Three hundred and eighty-five 
(51.4%) children qualified for rapid ART initiation within 7 days of HIV diagnosis or 
hospitalisation, based on CD4 criteria in the 2013 national Standard Treatment Guidelines.  
Overall mortality was 6.4% (CI: 4.9 - 8.4).  Mortality was significantly higher in the ICU 
cohort i.e. 14 (13.2%) deaths compared to 28 (5.5%) and 5 (3.9%) deaths in the GMWs and 
OHCs cohorts, logrank p=0.004.  Predictors of mortality included being moderately 
underweight HR 2.4 (CI: 1.1 – 5.2; p=0.02), severely underweight HR 3.2 (CI: 1.6 – 6.5; 
p=0.001), absence of caregiver counselling sessions HR 2.9 (CI: 1.4 – 6.0;   p=0.005) and 
ART initiation in ICU HR 2.6 (CI: 1.4 – 4.9; p=0.003). 
Conclusion:  The findings of our retrospective cohort study serve as a basis for 
understanding the implications of ART initiation in children during hospitalisation.  
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PART A: PROTOCOL 
Comparing short-term treatment outcomes of children started on ART in ICU versus 
general medical wards and outpatient department at the Red Cross War Memorial 
Children’s Hospital (RCWMCH): A Retrospective Cohort Study 
 
Background 
Paediatric populations are considered the most vulnerable of population groups globally, even 
more so since the emergence of HIV (Human Immunodeficiency Virus) and AIDS (Acquired 
Immunodeficiency Syndrome).  Global summaries  from  2009 estimate that 2.5 million 
children under the age of 15 years were infected with HIV and a further 260 000 paediatric 
deaths were due to AIDS-related illnesses.1  In South Africa, by mid-2009 approximately 340 
000 children under the age of fifteen were living with HIV.  Of these 70 000 were on 
antiretroviral therapy (ART).2   A study performed at Chris Hani Baragwanath Hospital in 
2007 not only described the disease profile of HIV infection in children but also highlighted 
missed opportunities for early initiation of ART.   Of the 94% of children diagnosed with 
HIV infection before admission to hospital only 46% were accessing ART even though 
94.5% met the ART eligibility criteria.3  Of the ART-naïve eligible children, only 4.1% were 
commenced on ART during the course of their admission.3  
Many studies have highlighted the increased mortality associated with HIV-infected children 
in the absence of ART and the importance of commencing therapy early.4  The World Health 
Organisation’s (WHO) 2006 paediatric ART guidelines stipulated that HIV-infected children 
should only be started on ART after specific clinical or immunologic criteria had been met.5 
However, the Children with HIV Early Antiretroviral Therapy (CHER) trial illustrated that 
mortality was in fact lower in children who commenced ART at a baseline age of 7 weeks 
regardless of clinical and immunologic criteria, compared to those in the deferred arm who 
commenced ART only once CD4 decline or disease progression occurred.6  
At the RCWMCH in Cape Town, of all the new ART enrolments between 2007 and 2011, 
79.45% were enrolments during admission and 49.6% were children under 6 months of age.7 
Treatment of children is often difficult to maintain for a number of reasons.  Their 
vulnerability as a whole makes them dependent on others for day-to-day care and nurturing.  
The responsibility of providing care lies predominantly on the caregiver rather than on the 
child, thereby emphasising the importance of adequate education and counselling of 
respective carers around issues essential for optimal treatment.8 Paediatric formulations are 
more complex and require regular dose adjustments due to the natural process of childhood 
growth and subsequent weight changes.  Formulations also require a certain degree of 
preparation (crushing of tablets, suspending and mixing exact ratios of water to powder) prior 
to being dispensed thereby further adding to the complexity of administering medication.8  
Drugs such as Kaletra are particularly unpalatable making it difficult for children, especially 
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those of a younger age group, to tolerate.  These, along with a host of other factors are 
thought to contribute greatly to treatment failure, morbidity and mortality.  
Virologic failure is defined as 2 consecutive unsuppressed viral loads, with the second being 
>1000 copies/ml, after 24 weeks of therapy.  Virologic failure has significant consequences 
for both the individual and the population at large.  For the individual, failure of suppression 
leads to an increased risk of morbidity and mortality.  The development of resistant strains 
places the remaining population at greater risk of contracting a more virulent organism; one 
which could potentially become resistant to multiple drug classes and subsequently become 
more difficult to treat.  In data analysed from children on ART in 7 Southern African 
treatment programmes in 2011, it was found that the 3 year probability of virologic failure 
among 5485 children was 19.3% (CI: 17.6 to 21.1).9  This suggests that even though the 
majority of children respond to treatment programmes, a large proportion remain 
unsuppressed and are failing treatment regimens. 
Clinical, virologic and immunological outcomes of HIV infected children started on ART 
have been previously assessed in various countries, including South Africa.  Formal research 
into factors that positively or negatively affecting these outcomes in a tertiary setting such as 
Red Cross War Memorial Children’s hospital has yet to be performed. This study aims to 
assess these factors and their influence on clinical, virologic and immunologic outcomes in 
order to indicate where efforts should be enhanced to optimise treatment. 
 
Aim 
The overall aim of this study is to compare the short term clinical, virologic and 
immunological outcomes of children started on ART in ICU versus those started on ART in 
the general medical wards and the outpatient HIV clinics at the Red Cross War Memorial 
Children’s Hospital and to assess the factors affecting these outcomes. 
Objectives 
The following research objectives were identified: 
- To determine factors predicting a good outcome (ie: suppressed 
viral load)  
- To assess survival and predictors of mortality and loss to follow-up 
within a 6 month period 
- To assess changes in viral load results, and CD4 counts and 
percentages after 6 months on ART 
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Methods  
Study Design, setting, participants and data collection 
This study design was a retrospective cohort study looking at the Paediatric ART programme 
at Red Cross War Memorial Children’s Hospital (RCWMCH).  Data from the Paediatric 
ART Programme from January 2008 up to and including December 2011 were extracted.  All 
ART-naïve children under the age of thirteen years, commenced on standardised 1st line ART 
therapy (according to the Department of Health National Guidelines), were included in this 
analysis.  Nine hundred and fifteen patient Folders and patient Clinical Record Forms 
(CRF’s) were reviewed for study eligibility by myself and Spasina King.  Thirty-seven 
records were excluded from the analysis due to duplicate or triplicate data records.  A further 
129 patients did not meet inclusion criteria.  Of these, 101 children were ART experienced 
and 28 had been initiated on ART at other health care facilities.  
Pre-treatment characteristics included patient age, gender, CD4 percentage and absolute 
count, viral load (VL), weight-for-age z-scores (WAZ), height-for-age (HAZ) and weight-for-
height (WHZ), World Health Organization (WHO) clinical staging, presence or absence of 
TB disease, ART initiation relative to TB treatment initiation, ART initiation relative to HIV 
diagnosis, ART initiation relative to hospital admission.  Pre-treatment WAZ scores, HAZ 
scores, CD4 and VL values included measurements within one month of ART initiation.  
Where multiple measurements were recorded values closest to ART initiation were used.  
Baseline primary and secondary co-morbidities as well as the degree of medical intervention 
needed were used to describe the severity of illness prior to ART initiation.  Patients were 
stratified into one of three groups based on the site of ART initiation.  These included the 
ICU, General Medical Wards (GMWs) and outpatient HIV clinics (OHCs) at RCWMCH. 
Due to the complexity of the variable age in paediatric patients, patient age was grouped into 
one of 4 categories: <3 months, 3-12 months, 13-60 months and >60 months.  CD4 counts 
and percentages, WAZ scores, HAZ scores, WHZ scores and VL were classified into groups 
according to the WHO criteria.     
A further sub-analysis was performed on patients transferred out to primary health care 
facilities within six months of starting ART. 
Outcomes and case definitions 
Outcome measures included: death, loss to follow-up (LTFU), virologic suppression and 
changes in CD4 count and percentage.  Outcomes were evaluated at 6 months using the 
measure taken closest to 6 months after initiation within a window of three to nine months 
after ART initiation.  LTFU was defined as failure to attend a follow-up visit for three 
months after the last scheduled appointment was missed.  Viral load suppression was defined 
as a viral load of <400 copies/ml and <50 copies/ml.  CD4 counts and percentages as well as 
viral loads were measured by the Western Cape Provincial laboratory services. 
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Statistical analysis 
Pre-treatment continuous variables were compared using ANOVA or Kruskal-Wallis, as was 
appropriate.  Frequencies and proportions were used to describe pre-treatment categorical 
variables.  Kaplan-Meier curves were fitted to estimate mortality, LTFU and attrition rates of 
patients between ART initiation sites.  Multivariable Cox proportional hazards regression was 
used to assess factors associated with mortality, LTFU and attrition after six months of ART, 
adjusting for pre-treatment clinical and demographic variables. 
Logistic Regression was used to assess factors associated with VL suppression of <400 
copies/ml and <50 copies/ml, again adjusting for pre-treatment clinical and demographic 
variables. 
Variables were assessed for inclusion in the regression analyses, based on results of the 
univariate analysis.  These included patient baseline factors (patient age, gender, WAZ, HAZ, 
WHZ, CD4 count and percent, VL, WHO clinical staging, presence or absence of TB disease, 
ART initiation site), maternal/primary caregiver factors (reported maternal HIV status at 
ART initiation, MTCT (mother to child transmission)  prophylaxis, maternal ART use at 
ART initiation, primary caregiver relationship to the child, caregiver support).  
Quantitative and qualitative data was analysed using the STATA Release 12.0 statistical 
software package (STATACorp, College Station, USA).  
Ethical consideration 
Ethical approval was obtained from the University of Cape Town’s Ethics Committee in 
2003 (HREC REF: 261/2002). 
As this was a retrospective review of patient information, no risks were incurred to the 
patients. 
There are no direct benefits to the participants however the following will contribute to an 
anticipated gain in scientific knowledge:  
- The recognition of factors inhibiting virologic suppression of 
patients on ART therefore highlighting areas where efforts need to 
be targeted in order to improve overall outcomes in HIV infected 
children. 
- The results would be generalizable to other institutions across the 
country as well as to areas sharing a similar demographic and socio-
economic profile as South Africa. 
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PART B: STRUCTURED LITERATURE REVIEW 
In 2012, 410 000 (370 000 – 450 000) children infected with HIV, were estimated to be 
living in South Africa.   At the end of 2012, an estimated 63% of 220,000 children <15 years 
of age qualifying for antiretroviral therapy (ART) in South Africa, were receiving therapy.1 
ART has been proven to decrease morbidity and mortality in HIV-infected children and 
improve immunologic, virologic and clinical outcomes.  The increasing number of children 
commenced on therapy in South Africa has encouraged outcomes research. Consequently, an 
emerging body of literature has begun to describe the impact of ART in HIV-infected 
children in South Africa. 
The purpose of this literature review is: 
1. To provide an overview of the immunologic, virologic and clinical outcomes of 
children and adolescents in South Africa started on antiretroviral therapy (ART) over 
the past 10 years. 
2. To summarize the impact of paediatric ART initiation at level 1, 2 and 3 health care 
facilities on these outcomes. 
3. To understand the impact of urban and rural settings on these outcomes. 
4. To identify gaps in knowledge around paediatric ART in a South African context 
requiring further research.  
 
Search Strategy 
A Pubmed search was used to extract literature relating to the above mentioned objectives.  
Inclusion criteria included citations related to outcomes of treatment naïve HIV-infected 
children and adolescents up to 19 years of age living in Southern Africa commenced on 1st 
line ART regimens in accordance to the national guidelines presiding at the time, over a 10 
year period extending from 01 July 2004 until 01 July 2014. 
 
 
 
 
 
 
 
 
 
Search Strategy: 
Outcomes of Children on ART in South 
Africa 
61 articles retrieved  
 
 
 
 
53 excluded 
Content not applicable to context 
of this literature review 
 
 
 
8 articles included in analysis 
25 articles in total included in analysis 
 
17 articles cross-referenced and included 
in analysis 
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Quality of Evidence 
Twenty-five articles were critically examined for the purpose of this literature review.  The 
remaining thirteen were policies, reports and publications used to enhance the context of this 
review.  Of the articles that were analysed, the majority were observational studies conducted 
retrospectively by accessing patient clinical records with only a few reporting results of 
randomised control studies.  Eleven were retrospective cohort studies, six prospective cohort 
studies, two retrospective cross-sectional studies and the remainder, randomised control 
studies.  Observational studies are typically low quality studies but are the most practical and 
feasible to conduct in over-burdened, understaffed public health care settings with high-
patient turnovers.  Randomised control trials provide a much higher quality of evidence, with 
increased validity and reliability of estimates.  Although the majority of published data 
extracted for this review is of an observational nature, the consistency of results in addressing 
the objectives outlined above increase the reliability of the findings.   
PUBLISHED DATA ON CHILDREN AND ADOLESCENTS RECEIVING ART  
First Author Year of 
Publication 
Study Period Geographic 
Location 
Setting Study 
Design 
Age 
Spectrum 
Sample 
Size 
Temporal Trends in Baseline Characteristics at ART Initiation 
Fatti, G [5] 2011 01 January 2004 – 30 
September 2009 
South Africa Primary, 
Secondary 
Retrospective 
Cohort Study 
< 16 years 3007 
Davies, MA 
[2] 
2013 01 January 2005 – 31 
December 2010 
Malawi, 
South Africa, 
Zambia, 
Zimbabwe 
Primary, 
Secondary, 
Tertiary 
Retrospective 
Cohort Study 
< 16 years 30 300 
(#15872) 
Immunologic, Virologic and Clinical Outcomes  
Reddi, A [6] 2007 31 August 2003 – 31 October 
2005 
South Africa Secondary Retrospective 
Cohort Study 
< 16 years 151 
Davies, MA 
[7] 
2009 01 June 1999 – 29 February 
2008 
South Africa Primary, 
Secondary, 
Tertiary 
Prospective 
Cohort Study 
< 16 years 6078 
Davies, MA 
[8] 
2011 01 June 1999 – 29 February 
2008 
South Africa Primary, 
Secondary, 
Tertiary 
Prospective 
Cohort Study 
< 16 years 5485 
Meyers, T [9] 2011 01 April 2004 – 31 March 
2008 
South Africa Tertiary Retrospective 
Cohort Study 
< 15 years 2102 
Violari [11] 2008 August 2005 – February 
2007 
South Africa Tertiary Randomised 
Control Trial 
6 – 12 
weeks 
377 
Prendergast 
[12] 
2008 August 2005 – February 
2007 
South Africa Tertiary Randomised 
Control Trial 
4 - 5 weeks 60 
Fenner, L [13] 2010 January 1999 – December 
2008 
South Africa, 
Malawi, 
Mozambique, 
Zimbabwe 
Tertiary, 
Primary 
Retrospective 
Cohort Study 
< 16 years 8225 
(+6072) 
Anthropometric Changes  
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Chhagan, M 
[19] 
2012 September 2006 – July 2009 South Africa Tertiary Prospective 
Cohort Study 
< 12 years 151 
Gsponer [20] 2012 January 1997 – December 
2010 
Malawi, 
Zambia, 
Zimbabwe, 
Mozambique, 
South Africa 
Primary, 
Secondary, 
Tertiary 
Retrospective 
Cohort Study 
< 10 years 17 990 
($6749) 
Feinstein, L 
[21] 
2012 01 April 2004 – 31 March 
2008 
South Africa Tertiary Retrospective 
Cohort Study 
< 15 years 2399 
Shiau, S [22] 2013 08 April 2005 – 10 July 2007 South Africa Secondary Randomised 
Control Trial 
< 2 years 195 
Neurodevelopmental Outcomes with Early ART 
Laughton, B 
[23] 
2012 August 2005 – February 
2007 
South Africa Tertiary Randomised 
Control Trial 
6 – 12 
weeks 
90 
Smith, L 
[24] 
2008 February 2002 – December 
2003 
South Africa  Tertiary Prospective 
Cohort Study 
< 13 years 39 
Incidence of Otorrhoea with Early ART 
Hainline, C 
[25] 
2011 August 2005 – February 
2007 
South Africa Tertiary Randomised 
Control Trial 
6 – 12 
weeks 
113 
Effect of ART on the Risk of Incident Tuberculosis  
Martinson, NA 
[27] 
2009 September 1994 – June 2006 South Africa Tertiary Retrospective 
Cohort Study 
< 15 years 1132 
Immune Reconstitution Inflammatory Syndrome  
Smith, K [28] 2009 April 2005 – November 2006 South Africa Secondary Prospective 
Cohort Study 
< 2 years 169 
Rabie, H [29] 2011 August 2005 – February 
2007 
South Africa Tertiary Randomised 
Control Trial 
6 – 12 
weeks 
369 
Treatment Outcomes of Adolescents  
Nglazi, MD 
[33] 
2012 September 2002 – June 2009 South Africa Primary Prospective 
Cohort Study 
9 – 28 
years 
883 
(*65) 
Nachega, JB 
[34] 
2009 January 1999 – August 2006 Southern 
Africa 
Private - 
sector 
Retrospective 
Cohort Study 
11 - >30 
years 
7776 
 
(‡154) 
Impact of ART Initiation at Primary, Secondary and Tertiary Health Care Facilities on Clinical Outcomes  
Bock, P [10] 2008 April 2004 – April 2006 South Africa Primary, 
Secondary, 
Tertiary 
Retrospective 
Cohort Study 
< 15 years 1741 
Dramowski, A 
[36] 
2011 01 October 2007 – 31 
December 2007 
South Africa Tertiary Retrospective 
Cross-
sectional 
Study 
< 14 years 1510 
Meyers, T [37] 2012 01 July 1996 – 31 January 
2011 
South Africa Tertiary Retrospective 
Cross-
sectional 
Study 
< 15 years 3063 
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Outcomes in Rural versus Urban Settings 
Fatti, G [38] 2010 01 November 2003 – 31 
March 2008 
South Africa Secondary, 
Primary 
Retrospective 
Cohort Study 
< 16 years 2332 
# 15 872 of children included in analysis were receiving ART at South African health care facilities. 
$ 6749 of children included in analysis were receiving ART at South African health care facilities. 
+ 6072 of children included in analysis were receiving ART at South African health care facilities. 
* 65 of cohort were adolescents (9-19 years). 
‡154 of cohort were adolescents (11-19 years). 
 
Interpretation of Literature 
 
Temporal Trends in Baseline Characteristics at ART Initiation 
Two studies have examined temporal changes in the characteristics of children starting ART 
in South Africa. In December 2013, the IeDEA-SA Collaboration published data from 4 
countries examining temporal changes in characteristics of children at the time of ART 
initiation across Southern Africa between 2005 and 2010.2   The principal findings of this 
study revealed that the median age of ART initiation declined from 63 months in 2006 to 56 
months in 2010.  The proportions of children <1 year increased from 12% to 19% and 
children ≥10 years, from 18% to 22% (probably reflecting the change in WHO policy at the 
time3).  As policies evolved, an emphasis on early infant testing was adopted.4 Younger 
children were being diagnosed and initiated on ART before the onset of severe disease 
progression.  This is reflected in this analysis in which children, including infants, showed 
significant declines in the percentage with severe immunosuppression, WHO stage 3 and 4 
disease and weight-for-age z-scores (WAZ) <-3 at ART initiation.  Another study looking at 
temporal trends in characteristics of children at the time of ART initiation from 2004 to 2009, 
but focusing on those in a South African context, yielded similar findings.5  The proportions 
of children <18 months initiating ART increased from 6.8% to 10.8% and from 15.3% to 
24.8% in children ≥10 years.  The median age however, comparatively increased from 5.8 
years in 2004 to 6.7 years in 2009.  Significant declines over time were again noted in the 
percentage with severe immunosuppression and in those with WHO stage 3 and 4 disease.  
Median CD4 percentage increased from 10.8% to 13.0% between 2004 and 2009, while the 
proportion of children with severe immunodeficiency decreased from 85.5% to 64.5% during 
this period.  The proportion of children with WHO stage 3 and 4 disease decreased from 
72.9% to 49.0%.  These changes in temporal trends once again reflect changes in policy at a 
global and national level, focusing on early infant testing, initiation of ART in children at 
younger ages irrespective of degree of immunodeficiency and WHO clinical staging as well 
as expanding CD4 threshold values for starting ART in older children.  
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Immunologic, Virologic and Clinical Outcomes 
A number of cohort studies have demonstrated good clinical, immunologic and virologic 
outcomes among children initiating ART. 
In March 2007, a retrospective cohort study was performed in Kwazulu-Natal looking at 
preliminary outcomes of children initiated on ART at Sinikithemba HIV/AIDS clinic.6  The 
median increase in CD4% from baseline was 10.2 percentage points at 6 months and 16.2 
percentage points at 12 months post-ART initiation.  At 6 and 12 months, 84% and 80.3% 
had undetectable viral loads respectively.  Kaplan Meier estimates predicted a 90.9% survival 
rate 12 months after initiation of treatment.  Another multi-cohort study looking at seven 
ART programmes in Gauteng, Western Cape and KwaZulu-Natal estimated the median 
change in CD4%, from baseline to be approximately 23%, 3 years post- ART initiation. 
Mortality and viral load suppression rates at 3 years were 7.7% and 80% respectively.7  In 
contrast to virologic suppression,  subsequent analysis on a largely similar cohort including 
the same seven South African ART programs estimated a 19.3%  probability of virologic 
failure by 3 years of treatment amongst over five thousand children commenced on first line 
ART. 8 The cumulative probability of immunologic failure at 3 years, defined according to 
South African guidelines was 12.6%.  Another treatment centre situated at a level 3 facility in 
Soweto, South Africa looked at ART responses amongst children attending the outpatient 
clinic.9  ART was initiated in slightly older children with a median age of 4.3 years compared 
to those in hospital settings, which tend to provide treatment to much younger children who 
already have severe disease progression.  The mean CD4% increased from 12.7% at baseline 
to 25.1% within 12 months of initiating treatment and subsequently continued to increase to 
reach 30.6% by 36 months.  This change in CD4% occurred at a faster rate in children less 
than 18 months of age.  84% of children initiated on ART achieved virologic suppression by 
12 months and 96% by 24 months.  The rate of mortality was only 4.2 deaths per 100 child-
years which is again less pronounced than in-hospital mortality rates10 reflecting the more 
stable and less immunocompromised nature of children attending outpatient clinics.  The 
proportion of children experiencing virologic rebound after initial suppression increased 
progressively over time from 1.3% at 6 months, to 11.6% and 16.3% at 24 and 36 months 
respectively.  Concomitant TB treatment, especially among children < 3 years receiving a 
Lopinavir/Ritonavir-based regimen was associated with an increased hazard of viral rebound.  
This could be explained by the drug interaction between rifampicin-containing TB treatment 
and the protease inhibitors. Children ≥ 3 years receiving an Efavirenz-based regimen were 
less likely to experience virologic rebound.          
There have been two clinical trials focusing mainly on outcomes of ART during infancy 
rather than older children, published in short succession of each other, with contrasting 
results.  The first, more commonly known as the CHER study reported findings of mean 
changes in CD4% post-ART initiation, in early and deferred-therapy groups of +5.9% and –
5.6% at 6 months and 4.5% and -4.8% at 8 months respectively. The results of this study 
further suggest that early HIV diagnosis and early initiation of ART in infancy significantly 
reduces mortality by 76% and HIV disease progression by 75%.11  In contrast to the CHER 
study, the Prendergast trial showed the difference in mortality between early and deferred 
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treatment to be negligible and not statistically significant.12  This contrast is most probably 
due to differences in trial designs and sample sizes used across the two studies.  The CHER 
study was a fully-powered randomized controlled trial whereas the Prendergast trial was a 
pilot randomized controlled trial designed as a feasibility study evaluating three different 
approaches to ART in HIV-infected children, rather than a study primarily assessing 
virological responses.  Fewer differences were noted across the groups due to low patient 
numbers.  More intensive follow-up and easier access to medical care within the dedicated 
study setting, could have also accounted for the favourable outcomes obtained across the 
treatment groups.  
LTFU is a common phenomenon found in many paediatric ART programs, especially those 
in resource-limited settings.  LTFU in children proves more challenging compared to adults 
as children form a more vulnerable group of the population and are largely dependent on 
caregivers for support and continued care.  Caregivers affected by ill health or death often 
directly influence the outcomes of children on ART.  In addition, a substantial proportion of 
paediatric ART services are located at larger health care facilities situated in urban areas 
resulting in limited access to care due to increased travelling distances and increased 
transport costs.  The inconvenience of having to attend different clinics compared to 
respective adult caregivers may also contribute to barriers in care.13  Data from studies 
mentioned above have reported rates of LTFU ranging of 8.2%7 and 7.0%13 at 1 year and 
4.4% at 3 years post-ART initiation.9  LTFU has also been shown to contribute substantially 
to an underestimation of mortality rates.  Data extracted from the IeDEA-SA collaboration 
estimated mortality for children remaining in care, to be below 5% but 8.7% in children at a 
program level across across both tertiary and community-based sites, when taking the likely 
mortality amongst those LTFU into account.13  This highlights the potential bias of LTFU in 
mortality estimates. 
Anthropometric Changes 
Growth failure has been well documented among HIV-infected children not receiving 
ART.14,15,16 Poor nutritional status is also highly correlated with a poor prognosis in untreated 
HIV-infected children.17  Anthropometric improvement has previously been documented in 
other African cohorts in response to ART.18  A prospective study of a cohort of HIV-infected 
children commencing ART at the King Edward VIII Hospital in Durban, South Africa 
revealed a significant improvement of mean WAZ and HAZ by 0.86 and 1.37 respectively, 
over a 2 year period.19  The steepest increase in WAZ was observed within the initial 6 
months of ART.  On average, almost normal rates of weight gain were achieved by 2 years of 
treatment.  Mean HAZ showed a more gradual increase with the greatest increase being 
observed in the second year of treatment.  Although improvements in HAZ were noted, 
children who manifested stunting at baseline continued to have significantly lower HAZ 2 
years after ART initiation possibly reflecting the role of altered hormone milieu early on, 
attributed to chronic malnutrition and co-infections associated with untreated HIV infection.  
Similarly, findings published in an analysis looking at growth responses to ART over a 3 year 
period, reported a rapid increase in WAZ and WHZ scores within the first year with 
significant tapering or reversal thereafter.  HAZ scores comparatively, showed a more 
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gradual increase  which persisted over time.20  Another study conducted at a clinic in Soweto, 
South Africa showed that 81% of underweight HIV-infected children achieved normal weight 
recovery within 2 years of initiating ART.21  Kaplan-Meier estimates suggested that younger 
children who were severely underweight at the start of ART were more likely to achieve 
recovery to normal weight bands compared to older children.  Only 64% of stunted children 
achieved height recovery within the first 2 years of ART once again suggesting that a 
sizeable proportion of children do not achieve adequate stature improvement during the early 
stages of ART.  The more severe the degree of stunting at ART initiation, the less likely was 
recovery to a normal height.  Older children (older than 35 months) were less likely to 
achieve recovery to a normal height than younger children.  A severe degree of 
immunosuppression at ART initiation did appear to influence growth recovery.  Data 
collected and analysed from the Rahima Moosa Mother and Child Hospital in Johannesburg 
reported similar findings with regards to younger children experiencing more rapid increases 
in WAZ and HAZ as compared to older children, especially if ART was initiated during the 
first 6 months of life.22  
Neurodevelopmental Outcomes with Early ART 
Neurodevelopmental delay is a well-documented phenomenon occurring commonly in HIV-
infected children not receiving ART.  Early ART initiation has been shown to significantly 
improve neurodevelopmental outcomes in HIV-infected children.23  In a sub-analysis of the 
CHER study, better short-term outcomes were experienced by children who start ART at an 
early stage compared to those in whom treatment was deferred. A comparison of mean scores 
on the Griffiths Mental Development Scales shows that all scores were lower in the deferred 
group compared to the early ART group.  General and locomotor scores were significantly 
lower.  Most scores in the early ART group were comparable to those in the HIV-uninfected 
(HIV-exposed and HIV-unexposed) groups.  The only exception was the locomotor scores 
wherein the HIV-exposed uninfected group performed better than the early ART group.  
In another study conducted at a tertiary centre in Cape Town no improvement was found in 
the neurodevelopmental outcomes of children commenced on ART.24  This study however, 
looked at children over a shorter follow-up period of 6 months in comparison to the CHER 
study, which followed up children over a longer time period.  Children were also older and 
had more advanced immunosuppression compared to those in the CHER study.   Forty-four 
percent and 56% had Centre for Disease Control (CDC) clinical category B and C disease 
respectively and 92%, severe immunosuppression.  As a result, neurological and cognitive 
deficits were already present prior to the onset of ART. Non- reversal of deficits subsequent 
to initiation of ART, were thought to be due to arrested encephalopathy and persistent poor 
socio-demographic factors.  
Incidence of Otorrhoea with Early ART 
Otorrhoea, commonly associated with chronic suppurative otitis media, is classified as a 
WHO stage 2 event for HIV-infected children.  It’s particularly associated with impaired 
hearing and ultimately affects comprehension, language skills and development especially in 
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those of a school-going age.  Another sub-analysis of the CHER study looked at the role of 
early ART in reducing the incidence of otorrhoea.25  Early ART was associated with 
significantly less otorrhoea compared to deferred treatment initiation.  Those in the deferred 
group had 3 times the risk of developing otorrhoea compared to those receiving early 
treatment. 
Effect of ART on the Risk of Incident Tuberculosis 
Tuberculosis (TB) is a condition commonly associated with HIV infection.  Although 
difficult to definitively diagnose, especially in HIV-infected children, it has been estimated 
that children aged 0-14 years constitute between 16% and 21% of all TB notifications in 
settings carrying a high burden of disease.26  In a multi-centre retrospective cohort study of 
HIV-infected children in South Africa, the incidence of any TB episode per 100 person-years 
before ART initiation was 16.4 compared to 6.3 in children on ART.27  ART was associated 
with a 70% reduction in risk of all-case incident childhood TB and a strongly protective 
effect in incident, culture confirmed TB.  Increasing age and increasing CD4% were also 
protective against TB.  For each year of age increase, an 11% and 17% reduction in risk for 
all cases of TB and culture confirmed cases of TB respectively was noted.  For every 
percentage increase in CD4%, a 0.04% reduction in risk was observed.  Due to the low yield 
of smear positive and culture confirmed TB and the inability to definitively diagnose TB in 
children these results may in fact underestimate the burden of disease in HIV-infected 
children.  Disease prevalence and incidence may be higher than what was observed in the 
context of this study. 
Immune Reconstitution Inflammatory Syndrome 
Immune reconstitution inflammatory syndrome (IRIS) is a condition associated with those 
initiating ART on a background of advanced HIV disease and low pre-treatment CD4 cell 
percentages / counts.  In 2009, results of a prospective cohort of HIV-infected children under 
2 years initiating ART were analysed.28  Twenty-one percent of children developed some 
degree of IRIS.  Seventy-three and a half percent manifested symptoms within 30 days of 
initiating ART.  Fourteen point eight percent of the total treatment cohort and 70.6% of those 
who developed IRIS, experienced BCG-related (bacille Calmette-Guerin) complications 
which is higher than reported in other studies.11  Risk factors included younger children, 
lower pre-treatment CD4 cell percentages, higher pre-treatment viral loads and lower WAZ 
scores.  Children with IRIS were less likely to achieve viral suppression after 24 weeks of 
treatment compared to those who did not manifest symptoms.  Eight point eight percent of 
those who developed IRIS died.  The CHER study more recently looked at the effect of early 
ART initiation on reducing the risk of BCG immune reconstitution adenitis.29  The rate of 
BCG-IRIS reported was far lower than reported in the above findings, with only 8.7% of 
children developing symptoms within 6 months after ART initiation.  Early initiation of 
ART, prior to immune suppression and HIV disease progression was again associated with a 
reduction in risk of BCG-IRIS.  
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Treatment Outcomes of Adolescents 
Little is known about treatment outcomes of HIV-infected adolescents, particularly those 
between 15 and 19 years of age.  Adolescence in itself is a challenging time where risk-taking 
behaviour, experimentation and peer-influenced behaviour predominates.  Management of 
infected adolescents becomes complex and challenging as many psychosocial factors come 
into play.  Data from well-resourced countries, have found low rates of ART adherence and 
increased risk of virological failure, LTFU and death in HIV-infected adolescents on ART.30, 
31, 32  One of the few studies performed in South Africa, looked at data extracted from a well 
established peri-urban clinic in Cape Town comparing treatment outcomes of adolescents 
aged 9 and 19 years, to those of young adults aged 20 and 28 years.33  Adolescents had lower 
rates of virologic suppression at 48 weeks than young adults (27.3% and 63.1% respectively) 
as well as increased rates of treatment failure (8.2 and 5.0 per 100 person-years respectively), 
in keeping with results of previous studies.  In a sub-analysis of perinatally infected 
adolescents and all infected young adults, similar rates of virologic suppression were 
obtained.  Rates of failure however, though higher in the perinatally infected adolescent 
group, were less marked compared the adolescent group as a whole.  The route of infection in 
young adults was not documented so direct comparisons of perinatally infected adolescents 
and young adults could not be made.  Median changes in CD4 count at 48 weeks however, 
were significantly greater for adolescents than for young adults (373 versus 187 cells/L).  
Surprisingly, there were no significant differences in LTFU or mortality between the two 
groups even though adolescence is associated with adverse behavior patterns.  Another study 
looked at records from HIV-1 infected adults and non-perinatally infected adolescents across 
9 countries in Southern Africa.34  Significantly fewer adolescents achieved 100% adherence 
at 6, 12 and 24 month follow-up periods compared to the adult group.  Adolescents who 
achieved viral load suppression, had a significantly shorter time interval to viral rebound.  
Adolescents were also less likely to experience long-term immunologic recovery, regardless 
of initial CD4 counts. 
Impact of ART Initiation at Primary, Secondary and Tertiary Health Care Facilities on 
Clinical Outcomes 
Primary/district, secondary and tertiary level health care institutions each have different 
experiences with regards to management and outcomes of HIV infection in paediatric 
populations.  Little data exists comparing clinical outcomes of HIV-infected children on 
ART, across these different levels of care.  In 2008 a retrospective review of all children 
started on ART in the Western Cape Province, South Africa looked at outcomes between 
2004 and 2006.10  Increased mortality was found at level 2 and 3 hospital facilities with 
estimated cumulative death rates being higher at 6, 12 and 18 months, post-ART initiation.  
This phenomenon was most probably reflective of the natural recruitment of sicker patients 
requiring more specialised and intensive care at a regional and tertiary level.  Rates of LTFU 
were similar across all levels of care.  No significant differences between viral load 
suppression rates and CD4% increases of >20%, across different levels of care were found 
suggesting that HIV-infected children receiving ART with uncomplicated disease, can be 
effectively managed at a basic level of care.  In 2000, a study conducted at a major tertiary 
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hospital in Johannesburg, South Africa looked at the contribution of paediatric HIV infection 
to in-hospital mortality rates over a 4 year period.35  These results reflect the state of 
paediatric HIV infection before the introduction of ART.  In those above 15 months of age, 
who were tested for HIV, 4.9% tested positive in 1992 and 35% in 1996, suggesting an 
increasing trend in the number of incident paediatric HIV infected cases detected.  In children 
under 15 months of age, 9% tested positive in 1992 and 46% in 1996.  A larger proportion of 
infected children (16.9%)   died within the first year of life in comparison to uninfected and 
untested children (6.4 and 3.7% respectively).  The proportion of hospital deaths occurring in 
children diagnosed with HIV infection significantly increased from 6.7% in 1992 to 46.1% in 
1996 thereby emphasizing the rapid degree of disease progression and associated comorbidity 
in the absence of ART.  Comparatively, a study performed at the same tertiary institute 
approximately 10 years later surprisingly revealed very similar findings, even after the onset 
of the national PMTCT (Post Mother to Child Transmission) programmes and ART roll-out 
in South Africa in 2004.36 Missed opportunities for prevention of mother-to-child 
transmission (PMTCT), delayed HIV diagnosis and delayed ART initiation reflecting 
programmatic failures, were all thought to contribute to these persistently high rates of 
infection in children. Delayed HIV PCR (Polymerase Chain Reaction) testing occurred in 
87.5% of infants between the ages of 6 weeks and 6 months.  Of this group, 45.6% received 
no PMTCT intervention at all, prior to diagnosis.  As was reported in previous studies, the 
highest case fatality rate was seen in infants less than 12 months.  More recently however, the 
same tertiary institute revealed more promising results with HIV prevalence among inpatients 
dropping from 26.2% in 1996 to 19.3% in 2010/2011.37  Rates of mortality also appeared to 
drop from 46.1% in 1996 to 12.3% in 2010/2011. The drop in prevalence and mortality 
probably reflects improved PMTCT coverage, early HIV testing and wider ART coverage in 
HIV exposed and HIV infected children.   
Outcomes in Rural versus Urban Settings 
A large proportion of HIV-infected children in South Africa live in rural settings 
characterised by inadequate housing, poor sanitation low rates of literacy, inadequate 
vaccinations and limited access to health care services.  Little data exists describing the 
outcomes of these children after ART initiation.  A retrospective cohort study was published 
in 2010 looking at the comparison of outcomes of HIV-infected children after initiation of 
ART, in rural and urban health care settings in four provinces across South Africa.38  At 
baseline, children starting ART in rural settings were older, had the lowest median baseline 
CD4 percentage reflecting a more advanced state of immunosuppression and the lowest mean 
baseline WAZ score suggesting a greater degree of wasting.  This most probably reflects a 
delayed access to ART in this group of children.  Mortality after 24 months of starting ART 
was significantly higher in the rural group and showed the greatest peak between all groups, 
during the first 6 months of treatment.  Kaplan-Meier estimates showed a 2.41 increased 
probability of mortality in rural versus urban children, after adjusting for baseline 
demographic and clinical variables.  Rates of loss to follow up (LTFU) were highest in rural 
children travelling to urban settings which was probably a reflection of increased travelling 
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distances to urban health care facilities, lack of transportation and financial constraints. These 
results highlight the relative vulnerability of children treated in rural settings 
 
Research Gaps Still to be Addressed 
Although advances have been made in understanding the natural progression of HIV-
infection in children as well as the effect of ART on their immunologic, virologic and clinical 
outcomes at both a national and global level, many aspects of treatment are still incompletely 
understood.  The following are a gaps in knowledge identified within a South African 
context, whilst performing this literature review: 
1. The immunologic, virologic and clinical outcomes of children transferred out to 
health care facilities other than the site of ART initiation and the effect it has on rates 
of mortality and loss to follow up. 
2. The long-term (> 4 years) effect of ART on anthropometric measures in HIV-infected 
children including the effect hormonal changes during puberty and adolescence with 
respect to growth trends and cath-up growth. 
3. Long-term neurodevelopmental outcomes and cognitive function of peri-natally 
infected children started on ART early on in life. 
4. The long-term effect of chronic otorrhoea on hearing / speech / comprehension and 
development in HIV-infected children. 
5. Treatment outcomes of adolescents, particularly those between 15 and 19 years of 
age. 
6. Treatment outcomes of children started on ART at different levels of care within a 
tertiary health care setting. 
7. The effect of ART on incidence and spectrum of opportunistic infection. 
The following analysis, attempts to bridge the gap in knowledge on treatment outcomes of 
children initiated on ART at different levels of care within a tertiary level hospital and to 
assess the impact of these different levels of care on short term clinical outcomes. 
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PART C: DISSERTATION 
 
ABSTRACT 
Short term treatment outcomes of children starting ART in the ICU, general medical 
wards and outpatient HIV department at Red Cross War Memorial Children’s Hospital 
(RCWMCH): A Retrospective Cohort Study 
Vashini Pillay, Mary-Ann Davies, Spasina King, Brian Eley 
 
Background: Many HIV-infected children are initiated on ART during hospitalisation in 
South Africa.  No published data on these outcomes exist.   
Objectives:  We assessed the short-term outcomes of children initiated on ART in the 
intensive care unit (ICU), general medical wards (GMWs) and outpatient HIV clinics (OHCs) 
at RCWMCH.  
Methods:  We conducted a retrospective cohort study of HIV-infected children <13 years of 
age, commenced on first line ART between January 2008 and December 2011 at Red Cross 
War Memorial Children’s Hospital.  Outcome measures included death, virologic suppression 
and changes in CD4 count and percentage.  Kaplan-Meier estimates, multivariate Cox 
proportional hazard ratios and logistic regression were used to estimate outcomes 6 months 
after ART initiation. 
Results:  Seven hundred and forty-nine children were included:  106 were commenced on 
ART in the ICU, 509 in the GMWs and 127 in the OHCs.  Sixty-five point seven percent of 
all children were <12 months.  Children in the ICU and GMW cohorts were significantly 
younger than the OHC cohort (median ages: 3 and 5 months respectively vs. 22 months) and 
had lower WAZ scores (-2.48 and -2.33 respectively vs -1.14).  One hundred and eighty two 
(24.9%) children qualifying for rapid ART initiation according to the 2013 national Standard 
Treatment Guidelines were commenced on therapy.  Overall mortality was 6.4% (CI: 4.9 - 
8.4). Mortality was significantly higher in the ICU cohort i.e. 14 (13.2%) compared to 28 
(5.5%) and 5 (3.9%) deaths in the GMWs and OHCs cohorts, logrank p=0.004.  Predictors of 
mortality included being moderately underweight HR 2.4 (CI: 1.1 – 5.2), severely 
underweight HR 3.2 (CI: 1.6 – 6.5), absence of caregiver counselling sessions HR 2.9 (CI: 
1.4 – 6.0) and ART initiation in ICU HR 2.6 (CI: 1.4 – 4.9). 
Conclusion:  These findings serve as a basis for understanding the implications of ART 
initiation in children during hospitalisation.  
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DISSERTATION 
Background  
Without antiretroviral therapy (ART) HIV infection progresses rapidly in children in low and 
middle income countries (LMICs). The majority of infected children have manifested with 
clinical features of HIV infection by 12 months of age .[1-4]  A pooled analysis looking at 
mortality in HIV-infected children living in Africa showed that without optimal therapy 
35.2% and 52.5% died by 12 and 24 months of age, respectively.[5]   Infants who are 
perinatally infected are particularly vulnerable.  Mortality at 12 months post-infection was 
shown to be almost twice as high in perinatally infected children compared to postnatally 
infected children (52% versus 26%) in the absence of ART.[6] Reliable CD4 count and 
percentage predictors of disease progression have not been identified among HIV-infected 
infants.[4,7]  
The CHER Study showed that if ART was commenced during the first 3 months of life in 
predominantly asymptomatic HIV-infected infants with limited immunological suppression, 
mortality risk was reduced by 76% and disease progression by 75%.[8]  Consequently 
treatment programs in LMICs have progressively increased access to universal ART for 
infected children. In April 2008 the World Health Organization (WHO) recommended ART 
for all HIV-infected children under 12 months of age irrespective of CD4 thresholds and 
WHO clinical stage.[9]  In July 2010 this directive was extended to all HIV-infected children 
under the age of 24 months and in July 2013 universal ART was recommended for all HIV-
infected children under 5 years of age.[10,11]  In South Africa, ART for all HIV-infected 
children under the age of 12 months was implemented in December 2009.[12]  In March 2013, 
this policy was extended to all HIV-infected children under 5 years of age, and in addition, 
expedited initiation of ART within 7 days of HIV diagnosis was recommended for all 
children under the age of 12 months as well as for children more than 12 months of age with 
WHO stage 4 disease and / or a CD4 count < 200 cells/mm3 or < 15%.[13]  
Although these policy changes have encouraged increased access to ART, treatment coverage 
among HIV-infected children has remained relatively low in South Africa resulting in high 
hospitalisation rates among HIV-infected children due to severe co-morbidity. At the end of 
2012, an estimated 63% of 220,000 children <15 years of age who required therapy were 
actually receiving ART in South Africa.[14]  At Chris Hani Baragwanath Hospital despite 
significant decline in HIV prevalence and inpatient mortality among all children hospitalised 
from 1996 onwards, 18.4% of all children admitted to that hospital in 2010 – 2011 were HIV-
infected, many of whom were ART-naive.[15]  Similarly, at Red Cross War Memorial 
Children’s Hospital (RCWMCH) HIV prevalence among children admitted to the general 
paediatric wards declined from 27.6% in 2007 to 17.9% in 2010.[16,17]  The majority of HIV-
infected children requiring hospitalisation at RCWMCH are ART-naïve infants, including 
many young infants. The median age of 1360 children initiated on ART at the hospital over a 
6-year period was 8 months and 25% were ≤3 months of age.[18]  Because the majority of 
HIV-infected children hospitalized at RCWMCH are infants with severe co-morbidity, 
initiating ART during hospitalisation is a common clinical practice at RCWMCH.[19]  In 
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contrast, in 2011 Chris Hani Baragwanath Hospital reported that only 4.1% of ART-naïve 
children, eligible for treatment over a 2 month period in 2007 were actually initiated on ART 
during hospitalisation.[20]  ART coverage during hospital admission was therefore low despite 
it being an established paediatric ART service.  Most publications of paediatric ART 
outcomes focus on children started on ART in outpatient clinics.  With the advent of the 2013 
national guidelines, especially the recommendation to expedite ART initiation for all infants 
as well as children with severe clinical or immunological disease, it is likely that larger 
numbers of young, HIV-infected infants and children at other health care facilities across 
South Africa are being initiated on ART during hospitalisation.  No published local studies 
have however, reported the outcomes of children initiated on ART during hospitalisation. To 
address this question, we undertook the present study in which the short term outcomes of 
children initiated on ART in the intensive care unit (ICU), general medical wards (GMWs) 
and outpatient HIV clinics (OHCs) at RCWMCH were described. 
   
Methods 
Study location 
This study was undertaken at RCWMCH, a tertiary referral hospital in Cape Town, South 
Africa, dedicated to the care of children up to 13 years of age. The hospital provides inpatient 
care, intensive care and outpatient follow-up for HIV-infected children.  
Study design, inclusion criteria & baseline data collection 
A retrospective cohort study was conducted. Children qualified for inclusion if they were less 
than 13 years of age and commenced on first-line ART between January 2008 and December 
2011 at RCWMCH. A list of all children receiving ART during the study period was 
extracted from a Microsoft Access Database containing information on children treated with 
ART at RCWMCH. Children meeting the inclusion criteria were identified and data relating 
to their ART history was retrieved. Additional baseline patient clinical information and 
maternal information including counselling practices were, extracted retrospectively from 
patient hospital records. Data collected prior to starting ART included age, gender, CD4 
percentage and absolute count, plasma HIV RNA concentration (viral load), body mass and 
length / height, WHO clinical stage, the presence or absence of active tuberculosis and the 
time interval between HIV diagnosis and ART initiation. Age was grouped into one of 4 
categories: <3 months, 3 - 12 months, 13 - 60 months and >60 months. Mass and 
length/height measurements were transformed into weight-for-age z-scores (WAZ), height-
for-age z-scores (HAZ) and weight-for-height z-scores (WHZ) using WHO 2006 Child 
Growth Standards.[21]  Moderate underweight, stunting and wasting were defined as WAZ, 
HAZ and WHZ between -2 and -3, respectively. Severe underweight, stunting and wasting 
were defined as WAZ, HAZ and WHZ below -3, respectively.   Baseline primary and 
secondary co-morbidities as well as the degree of medical intervention required were used to 
describe the severity of illness prior to ART initiation. Patients were stratified into one of 
three groups based on the site of ART initiation i.e. during ICU admission, GMW admission 
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or an OHC visit. Primary baseline clinical conditions were defined as the disease process that 
most likely contributed to the respective hospital admission and was determined by the 
attending clinician on duty. Extrapulmonary tuberculosis (EPTB) for the purpose of this 
analysis has been defined as a patient with tuberculosis involving organs other than the lungs 
such as pleura, pericardium, lymph nodes, abdomen, joints and bones and meninges.  
Counselling of caregivers by trained paediatric ART counsellors prior to ART initiation is 
usually practiced at RCWMCH.  The primary aim is to equip caregivers with the knowledge 
and skills needed to provide treatment to their children.  Three counselling sessions, each 
covering different aspects of the disease process, practical issues around treatment as well as 
a formal demonstration in administering ART to respective patients, are performed prior to 
and during the course of ART initiation. These sessions are formally documented on a 
prescribed checklist.  
Study outcomes 
Outcome measures included death, loss to follow-up (LTFU), attrition, virological 
suppression and changes in CD4 count and percentage.  Outcomes were evaluated at 6 
months using the measure taken closest to 6 months after initiation within a window of three 
to nine months after ART initiation.  Loss to follow-up was defined as failure to attend a 
follow-up visit within three months after the last scheduled appointment was missed.  
Attrition was defined as a combination of patients who had died and those who were LTFU 
during the study period. Two cut-off values were used to define virological suppression (i.e. a 
plasma HIV RNA concentration (viral load) <400 copies/mL or <50 copies/mL) in order to 
reflect the sensitivities of different viral load assays used in low resource countries.  HIV 
RNA measurements were performed using Abbott Realtime HIV-1 assay.[22]  CD4 
measurements were performed by the PanLeucogated method.[23]  
Statistical Analysis 
Pre-ART continuous variables were non-normally distributed and therefore compared using 
the Kruskal-Wallis test.  Frequencies and proportions were used to describe pre-treatment 
categorical variables.  Chi-squared test of association or Fisher’s Exact tests were used to 
assess associations between these variables.  CD4 percentage and viral load (VL) results at 6 
months were compared to the respective baseline results using the Wilcoxon signed-rank test 
for paired samples.   Kaplan-Meier curves were fitted to estimate mortality, LTFU and 
attrition probabilities during the first 6 months of ART.   
Multivariable Cox proportional hazards regression was used to assess factors associated with 
mortality, LTFU and attrition during the first six months of ART, adjusting for pre-treatment 
clinical and demographic variables. Logistic Regression was used to assess factors associated 
with an unsuppressed VL during the first 6 months of ART i.e. plasma HIV RNA 
concentration > 400 copies/mL or > 50 copies/mL, adjusting for pre-treatment clinical and 
demographic variables. Variables with p-values <0.1 on univariate analysis were included in 
the regression models. 
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The data was analysed using the STATA Release 12.0 statistical software package 
(STATACorp, College Station, USA).  
Ethical consideration 
The study was conducted in accordance with the Declaration of Helsinki, and was approved 
by Human Research Ethics Committee, Faculty of Health Sciences, University of Cape 
Town, reference number: HREC REF: 261/2002 
 
Results 
In total, 878 children were treated with ART at RCWMCH during the study period. Of these, 
129 were excluded from the analysis for the following reasons:  101 children were ART 
experienced and 28 had been initiated on ART other health care facilities.  Data from the 
remaining 749 children who fulfilled the inclusion criteria were analysed. 
Baseline Characteristics 
Tables 1 and 2 describe patient and caregiver characteristics prior to ART initiation. Of the 
749 included children, 106 (14.5%) were commenced on ART in the ICU, 509 (68.0%) in the 
GMWs and 127 (17.0%) in OHCs.  Seven hundred and thirty-two (97.7%) children would 
have qualified for expedited initiation of ART according to the 2013 South African national 
treatment guidelines. Of these, 492 were children < 12 months, 129 were children >12 
months with CD4 < 15% and 111 were children  >12months with WHO stage 4 disease.  One 
hundred and eighty-two of the 732 (24.9%) children who would have qualified for expedited 
initiation were commenced on ART within 7 days of diagnosis.  However, 367 (50.1%) were 
initiated within 7 days of hospital admission and a further 198 (27.0%) within 14 days. 
Children commenced on ART in the OHCs were significantly older than those in the ICU and 
GMWs. Overall, 65.7% of all children initiated on ART were <12 months old. The median 
age at ART initiation was lowest in the ICU cohort.  Those in the ICU and GMW cohorts had 
significantly lower median WAZ scores of -2.48 and -2.33  respectively when compared to 
those in the OHCs cohort, median WAZ of -1.14 (p=0.0001).  Wasting was more frequent in 
the ICU and GMW cohorts compared to the OHC cohort, although there was no significant 
difference in the frequency of wasting between these inpatient cohorts.  More than 75% of 
children had sub-normal CD4 percentages of less than 25%, and 385 (51.4%) children had 
CD4 < 15% and/or CD4 < 200 cells/mm3. More children who were initiated on ART in the 
ICU and GMWs had a baseline VL > 100,000 copies/ml. Younger children, particularly 
infants, presented with higher viral loads compared to older children.  The median VL log10 
value of children < 12 months was 6.0, while the median value of those > 60 months was 4.8  
(p=0.001).  Overall 24.7% of children had current tuberculosis.  Of those, 6.5% had culture 
confirmed disease and 19.2% probable tuberculosis.  Seventy-one point nine percent were 
treated for pulmonary tuberculosis (PTB) only, 20% for both PTB and EPTB and 8.1% for 
EPTB only.  The time from HIV diagnosis to ART initiation as well as the time from hospital 
admission to ART initiation was significantly shorter in the ICU cohort. No obvious 
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differences were noted in caregiver characteristics between the different cohorts prior to ART 
initiation.  Ninety-two point nine percent of caregivers underwent at least 1 counselling 
session at RCWMCH, while 53 (7.1%) caregivers received none.  Of caregivers not receiving 
counselling sessions, 61.4% were due to lack of caregiver availability during ART initiation, 
10.3% were due to patients being transferred out to other health care facilities before 
counselling sessions could be initiated, 17.2% were counselled during follow-up visits after 
discharge from hospital and 11.1% had no documentation of reasons counselling sessions 
were not performed. Table 3 describes the primary diagnoses of children admitted to the 
GMWs and ICU prior to ART initiation. Pneumonia was the predominant condition, present 
in 90.6% and 45.0% of children initiated on ART in the ICU and GMWs respectively.   
Outcomes at 6 months 
The Kaplan-Meier probability of overall mortality after 6 months of ART was 6.4% (95% CI: 
4.9, 8.4). The mortality estimate at 6 months was significantly higher in the ICU cohort i.e. 
13.2% (14 deaths) compared to 5.5% (28 deaths) and 3.9% (5 deaths) in the GMW and OHC 
cohorts, log-rank p=0.004, Figure 1(a).  Of those who died, median time to death after ART 
initiation was 25 days.  Of the deaths in the GMW and ICU cohorts, 38 (90.5%) occurred 
during the primary hospital admission.  6 (3.1%) children from the GMW cohort, 4 (3.2%) 
from the OHCs and 4 (2.4%) from the ICU were LTFU by 6 months after starting ART. No 
statistical differences were found in the probabilities of LTFU (log-rank p=0.78) or attrition 
between the three groups, log-rank p= 0.12, Figure 1(b).  
After 6 months of ART, 51.0% of children remaining in care at RCWMCH had achieved a 
CD4% ≥ 25% and 62.3% a viral load ≤ 50 copies/mL. Paired analyses documented a 
significantly greater increase in median CD4% over the first 6 months of ART among 
children initiated on ART in the ICU, but similar, substantial declines in the median log10 VL 
values among the three treatment cohorts.  The proportion of children achieving virologic 
suppression was significantly lower in the ICU cohort   (Table 4). 
Of the 749 patients analysed, 257 were transferred out to primary health care facilities for 
continuation of care, within 6 months of ART initiation.  Where possible, CD4 and viral load 
results after transfer-out were obtained from the Western Cape Provincial laboratory 
database.  Of those transferred out, 142 (55.3%) had CD4 count results and 109 (42.4%) had 
VL results available 6 months after ART initiation.  Paired analyses showed no significant 
differences in CD4 and VL log values at 6 months in those who were transferred out 
compared to those who remained in care at RCWMCH.    Median increases in CD4% at 6 
months in those transferred out and in those who remained in care were 4.0 and 5.8 
respectively (p=0.165).  Median decreases in VL log values at 6 months in those transferred 
out and in those who remained in care were 4.4 and 4.6 respectively (p=0.33) with no 
significant differences being found in proportions of children achieving virologic 
suppression.  Of patients who were transferred out, 10 (3.9%) were LTFU and 9 (3.5%) died. 
Outcomes of those transferred out were determined using linkage with the Western Cape 
Provincial laboratory database and folder reviews. Mortality ascertainment was based on 
documented death in the RCWMCH folder, usually after representing and being admitted to 
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RCWMCH. Children who had specimen results of any nature recorded on the National 
Health Laboratory Service (NHLS) database at 6 months post-ART initiation were 
considered alive.  Children with no record of specimen results post-transfer out and who were 
not documented to have died by 31st March 2013 were assumed LTFU.   
Predictors of mortality, attrition and an unsuppressed viral load 
The multivariate analysis examining factors that influenced mortality (Table 5) within 6 
months of ART initiation revealed the following:  children under 3 months of age had a 1.8  
fold  (CI: 0.97 – 3.4 ; p= 0.07) increase in mortality compared to older children.  Severely 
malnourished and moderately malnourished children had an increased hazard ratio of 3.2 (CI: 
1.6 – 6.5; p=0.001) and 2.4 (CI: 1.1 – 5.2; p=0.02) respectively compared to those who had 
mild-normal nutrition.  Children of caregivers who had received no counselling sessions prior 
to and during initiation of ART also had a significantly higher risk of experiencing death 
compared to those children who’s caregivers had received counselling (2.9 HR ; CI: 1.4 – 6.0 
; p=0.005).  Children initiated on ART in the ICU had a 2.6 increased hazard of death (CI: 
1.4 – 4.9; p=0.003) compared to those in the GMW and OHC groups.  Children with 
caregivers who were not on ART at baseline, had a decreased hazard of death (0.5 HR; CI: 
0.3 – 0.9; p=0.02).    
Regression modelling of those children who were LTFU within 6 months of ART initiation 
revealed that age was the only variable associated with LTFU; children between the ages of 3 
and 12 months had a 3.16 increased risk of LTFU (CI: 1.2 – 8.1 ; p=0.02) compared to older 
children. 
Factors influencing attrition (Table 6) within 6 months of ART initiation included patient age, 
WAZ scores, number of caregiver counselling sessions and caregivers who were on ART at 
baseline.  Older children between the ages of 13 and 60 months had a decreased hazard of 
attrition (0.5 HR; CI: 0.2 – 1.1; 0.08).  Children who were severely malnourished and 
children who had caregivers who did not receive any counselling sessions were at increased 
risk of attrition (1.8 HR; CI: 1.1 – 2.8; p=0.02 and 2.6 HR; CI: 1.4 – 5.0; p=0.003 
respectively).   
Logistic Regression looking at factors predicting failure to suppress after 6 months of ART 
(Table 7) revealed the following:  For both VL outcomes (VL > 50 copies/ml and VL > 400 
copies/ml), age was the major determinant in predicting failure to suppress.  Younger 
children were significantly less likely to suppress after 6 months of ART in both groups - 
35.8% of children under 12 months and 15.9% of children over 12 months did not achieve a 
viral load  <400 copies/mL within 6 months of ART start. In comparison to children >12 
months old at ART start, children under 3 months of age had a 3.1 fold increased risk of a VL 
> 50 copies/ml (CI: 1.8 – 5.3; p=0.001), while children between 3 and 12 months of age had a 
2.6 fold increased risk of a VL > 50 copies/ml (CI: 1.3 – 4.9; p=0.005) after adjusting for 
other predictors of virologic response.  Similarly, children under 3 months of age had a 3.0 
fold increased risk of a VL > 400 copies/ml (CI: 1.5 – 5.9; p=0.002) while children between 3 
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and 12 months of age had a 2.6 increased risk of a VL > 400 copies/ml (CI: 1.4 – 4.6; 
p=0.002). 
 
Discussion 
Our study shows that young ART naïve HIV-infected children are still very much at risk for 
HIV-related morbidity and mortality, particularly those under the age of 3 months.  The 
majority of children initiating ART at RCWMCH were <12 months old; 85.4% had WHO 
Stage 3 or 4 disease and 75.7% were immunocompromised (CD4 < 25%) at presentation to 
hospital. Nevertheless, our study demonstrates that it was feasible to initiate ART rapidly 
after admission even in sick children in our setting, with mortality of 6.4% overall and <15% 
even in the sickest children where ART was started in ICU. In addition, LTFU was <5% 
among all groups of children. While most children experienced immune recovery, the low 
proportion with virologic suppression by 6 months after ART start, especially among infants 
is a concern. 
The severity of illness at ART start is  consistent with an analysis of infants <3 months of age 
initiating ART across twenty public clinics in Cape Town and the ART service at the Chris 
Hani Baragwanath Hospital in Soweto between June 2007 and September 2010. Although the 
median age of children starting ART was 8.4 weeks; 62% of infants already had advanced 
HIV disease (CD4% < 25% or absolute CD4 < 1500 cells/mm3 or WHO clinical Stage 3 or 
4, suggesting  that ART initiation even as early as 3 months of age may not be  sufficient to 
prevent morbidity and mortality in young children.[24]  Previous studies have demonstrated 
that ART initiation in children at more advanced stages of disease, yields poorer clinical and 
immune recovery and outcomes.[25,26]  This highlights the need for even earlier HIV testing 
and diagnosis in infants as well as rapid initiation of ART in those who are infected. 
Our finding that 35.8% of children under 12 months and 15.9% of children over 12 months 
did not achieve a viral load  <400 copies/mL within 6 months of ART start is consistent with 
previous studies.  Poor responses in viral load suppression in young children especially those 
younger than 24 months were described in a Soweto clinic where the cumulative probability 
of achieving viral load suppression (< 400 copies/mL) by six months after ART initiation, 
was 59.4%.  Children older than 36 months were more likely to achieve virologic suppression 
at an earlier stage compared to those younger than 36 months.[27]  Failure to achieve virologic 
suppression in young children could be attributed to a combination of factors including 
palatability of drug formulations in young children resulting in poor adherence, high baseline 
viral loads in vertically HIV-infected infants possibly requiring longer time periods to 
suppress and choice of first-line ART drug regimens.  In 2011, the European Pregnancy and 
Paediatric HIV Cohort Collaboration analysed data across 13 European countries and found 
virologic and immunologic responses twelve months after ART initiation, to be superior 
using a 4-drug NNRTI-based regimen compared to a boosted PI-based or 3-drug NNRTI 
regimen.[28,29] 
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Growth failure has been previously documented among HIV-infected children not receiving 
ART.[30,31,32] Poor nutritional status has also been highly correlated with a poor prognosis in 
untreated HIV-infected children.[33]  Our results show that moderately and severely 
underweight children have a significantly increased risk of mortality during the first six 
months of ART compared to children who are only mildly underweight.  More children in the 
ICU and GMW settings were moderately to severely underweight compared to those children 
seen in the OHC.  This reflects the contribution a poor nutritional status prior to ART 
initiation has, on the clinical condition of children requiring admission to a tertiary level 
health care facility. 
Before the advent of ART, the majority of HIV-infected children in our setting required 
hospital admission to ICU facilities before reaching 6 months of age.[34] Mortality was high in 
the absence of ART, with rates of 27% and 44% being documented at the RCWMCH and 
Tygerberg Hospital in Cape Town, respectively.  Since the introduction of ART in children, 
mortality has decreased substantially.  Our study reports a mortality probability of 13.2% in 
children infected with HIV, admitted to the ICU  and subsequently commenced on ART, 
which although is significantly higher than those in the GMW and OHC’s, is approximately 
half of previously reported hospital mortality in children not receiving ART.  This could be 
due to a combination of factors including increased early HIV diagnosis and ART initiation 
resulting in children admitted to ICU being relatively less ill than those admitted in the pre-
ART era.  That being said, children requiring ICU care at admission, even during the era of 
ART are more ill on presentation to hospital which probably influences the clinical, 
immunologic and virologic outcomes and possibly explains the increased mortality rate 
compared to the GMW’s and OHC’s.  Our study reports that 90.6% of children admitted to 
ICU had an associated severe pneumonia requiring some level of assisted ventilation 
highlighting the severity of disease on presentation to hospital.   Severity of baseline clinical 
conditions have previously been of concern in relation to potential drug toxicity in the setting 
of multi-organ failure.[34]  Our results do therefore suggest that ART may have played a role 
in lowering ICU mortality.   Other factors possibly leading to improved outcomes include 
increased awareness and experience in managing ill HIV-infected children as well as 
improved treatment practices.  The exact nature and impact of these factors have, however, 
yet to be assessed. 
A quarter of children presenting to RCWMCH were diagnosed with tuberculosis either before 
or during presentation to hospital.  The majority were commenced on anti-tuberculous 
treatment prior to ART initiation in keeping with WHO and national guidelines.  The median 
time between initiating tuberculosis treatment and ART overall was 12 days.  In those 
admitted to ICU however, the median time to initiating tuberculosis treatment was 6.5 days 
after ART initiation.  Tuberculosis diagnosis was confirmed in only 6.5% of patients started 
on anti-tuberculous treatment reflecting the lack of accurate diagnostic tests available in 
diagnosing tuberculosis in HIV-infected children.   
Only 24.9% of children qualifying for expedited ART initiation according to WHO 2013 
criteria were commenced within 7 days of diagnosis.  This number is low probably due to the 
fact that we analysed data from Jan 2008 to Dec 2011 and guidelines for expedited initiation 
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were only implemented after 2013.  Also, 152 children were diagnosed outside of 
RCWMCH, mainly at primary health care facilities.  The proportion of children initiated on 
ART within 7 and 14 days of admission to RCWMCH was 49.0% and 75.4% respectively.  
South African national guidelines recommend ART initiation within 7 days of diagnosis in 
young children or in those with advanced disease though this may not prove practical at a 
program level.   
Psychosocial factors contribute substantially to successful outcomes of ART in children, in 
particular, counselling of caregivers prior to and during the course of ART initiation.  Our 
study demonstrates a greater than two-fold increased risk of mortality and attrition 
respectively, in the absence of caregiver counselling sessions. As most deaths occurred early 
and during the current hospital admission in hospitalized patients, lack of counselling is 
unlikely to have a causal effect on mortality. Indeed, the major reason for caregivers not 
receiving counselling was lack of caregiver availability during ART initiation, reflecting the 
likely rapidity of ART initiation in these patients and the challenge of providing counselling 
when expediting ART.    
Strengths and Limitations 
The strength of this study lies in its’ novel contribution to existing literature in relation to 
examining the impact of ART initiation at different levels of health care within a tertiary 
hospital setting.  It also provides an accurate reflection of health care function at an 
operational level in an over-burdened health care system with a high turnover of patients. 
Due to this being a retrospective analysis, limitations in availability of routine data such as 
feeding practices, were found.  Due to a high TFO rate of children to other health care 
facilities after ART initiation, access to follow-up clinical and laboratory data proved 
challenging.  In particular, six month follow-up anthropometric data, viral load and CD4 
results were lacking, impeding our ability to accurately reflect on growth patterns, 
immunologic reconstitution and virologic suppression amongst the original cohort of children 
initiated on ART at RCWMCH.  In general, children transferred out are less ill than those 
remaining in care.  Virologic and immunolgic outcomes of the entire cohort initially started 
on ART could in fact be better than reported, had we complete follow-up data on those 
transferred out.  The results of this study are not generalizable to the general HIV-infected 
paediatric population as the cohort of children included in this analysis were, by virtue of 
being admitted to a tertiary health care centre, more ill and displayed more severe forms of 
disease.  The catchment of patients itself, adds a degree of selection bias to this analysis.  The 
study was also restricted to those initiating ART as this was the primary focus. However this 
limits our ability to assess the feasibility of commencing ART in all severely ill children, 
some of whom may have died before treatment could be initiated. 
Similar studies at tertiary level health care facilities should be performed in order to 
corroborate our findings and provide a basis for developing and optimising consensus 
guidelines for managing severely ill HIV-infected infants and children. 
 
Conclusion 
These results highlight the importance of understanding the context in which children initiate 
ART when comparing outcomes in different settings. This study highlights that even with 
early diagnosis, many infants will already have advanced disease, and ART initiation in these 
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children may be challenging. While our study demonstrates the feasibility and good mortality 
outcomes of starting ART in very ill young children, there is a need to develop and optimize 
consensus guidelines for managing severely ill HIV-infected young infants and children in 
order to ensure optimal long term outcomes. 
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TABLES, FIGURES & LEGENDS 
Table 1: Characteristics of HIV-infected children prior to ART initiation 
 
 Overall Patient 
Baseline Characteristics 
Patient Characteristics Stratified According to ART Initiation Location 
Outpatient HIV clinics General Medical Wards ICU P-value 
Age in months  
(median,IQR) 
N=749 
5  (3 ; 23) 
N=127 
22  (5 ; 71) 
N=509 
5  (3 ; 21) 
N=106 
3  (3 ; 4) 
 
0.0001 
Age categories (%) 
<3 months 
3-12 months 
13-60 months 
>60 months 
N=749 
130  (17.4) 
362  (48.3) 
147  (19.6) 
110  (14.7) 
N=127 
14   (11.0) 
37   (29.1) 
39   (30.7) 
37   (29.1) 
N=509 
90    (17.7) 
247  (48.5) 
102  (20.047) 
70    (13.8) 
N=106 
25   (23.6) 
72   (67.9) 
6     (5.7) 
3     (2.8) 
 
 
0.0001 
Gender (%) 
Female 
Male 
N=749 
379   (50.6) 
370   (49.4) 
N=127 
60   (47.2) 
67   (52.8) 
N=510 
258   (50.6) 
252   (49.4) 
N=106 
57   (53.8) 
49   (46.2) 
 
0.61 
WAZ   
(median, IQR) 
N=700 
-2.14  (-3.42 ; -0.95) 
N=115 
-1.14  (-2.47 ; -0.23) 
N=477 
-2.33  (-3.56 ; -1.17) 
N=102 
-2.48  (-3.91 ; -1.37) 
 
0.0001 
WAZ categories (%) 
Mild-normal 
Moderate underweight 
Severe underweight 
N=700 
331   (47.3) 
141   (20.1) 
228   (32.6) 
N=115 
82   (71.3) 
14   (12.2) 
19   (16.5) 
N=477 
210   (44.0) 
109   (22.9) 
167   (35.0) 
N=102 
47   (46.1) 
17   (16.7) 
38   (37.3) 
 
0.0001 
HAZ    
(median, IQR) 
N=525 
-2.14  (-3.55 ; -0.95) 
N=121 
-1.92  (-2.84 ; -0.91) 
N=338 
-2.16  (-3.7 ; -1.1) 
N=61 
-2.00  (-3.72 ; -0.2) 
 
0.20 
 
HAZ categories (%) 
Mild-normal 
Moderate stunting 
Severe stunting 
N=525 
248   (47.2) 
110   (201.0) 
167   (31.8) 
N=121 
63   (52.1) 
34   (28.1) 
24   (19.8) 
N=338 
153   (45.8) 
64     (18.9) 
120   (35.5) 
N=61 
30   (49.2) 
10   (16.4) 
21   (34.4) 
 
0.02 
WHZ   
(median, IQR) 
N=446 
-1.2  (-2.61 ; -0.04) 
N=83 
-0.04  (-1.29 ; 0.8) 
 
N=297 
-1.53  (-2.8 ; -0.3) 
N=61 
-1.37  (-2.82 ; -0.31) 
 
 
0.0001 
WHZ categories (%) 
Mild-normal 
Moderate wasting 
Severe wasting 
N=446 
293   (65.7) 
70     (15.7) 
83     (18.6) 
N=81 
72   (88.9) 
7     (8.6) 
2     (2.5) 
N=297 
180   (60.6) 
50     (16.8) 
67     (22.6) 
N=61 
37   (60.7) 
12   (19.7) 
12   (19.7) 
 
0.0001 
CD4 percent 
(median, IQR) 
N=742 
17.00   (10.0 ; 24.6) 
N=127 
17.6   (10.4 ; 24.4) 
N=509 
17.12   (10 ; 25.3) 
N=106 
14.35   (8.9 ; 22.5) 
 
0.12 
CD4 percent (%) 
1   (>=25%) 
2   (<25%) 
 
N=742 
180    (24.3) 
562    (75.7) 
 
N=127 
29   (22.8) 
98   (77.2) 
 
N=509 
132   (25.9) 
377   (74.1) 
 
N=106 
19   (17.9) 
87   (82.1) 
 
 
0.27 
Viral Load   (%) 
1   (<100 000) 
2   (>100 000) 
N=691 
183    (26.5) 
508    (73.5) 
N=123 
58   (47.2) 
65   (52.9) 
N=465 
109   (23.4) 
356   (76.6) 
N=96 
15   (15.6) 
81   (84.4) 
 
0.0001 
Staging (%) 
Stage 1 
Stage 2 
Stage 3 
Stage 4 
N=741 
39       (5.3) 
62       (8.4) 
258     (34.8) 
382     (51.6) 
N=127 
9     (7.1) 
19   (15.0) 
68   (53.5) 
31   (24.4) 
N=502 
29      (5.8) 
40      (8.0) 
182    (36.3) 
251    (50.0) 
 
N=106 
1      (1.0) 
3      (2.8) 
6      (5.7) 
96    (90.6) 
 
 
0.0001 
TB Disease (%)  
None 
PTB 
EPTB 
PTB + EPTB 
N=743 
558   (75.1) 
133   (17.9) 
15     (2.0) 
37     (5.0) 
N=127 
82    (64.6) 
33    (26.0) 
8      (6.3) 
4      (3.1)        
N=504 
380    (75.4) 
87      (17.3) 
10      (1.98) 
27      (5.4) 
N=105 
89   (84.8) 
6     (5.7)    
4     (3.8) 
6     (5.7) 
 
 
0.0001 
Time to ART initiation 
relative to TB rx initiation 
(days) 
(median, IQR) 
 
 
N=173 
12     (24 ; 1) 
 
 
N=43 
29   (92 ; 16) 
 
 
N=114 
9      (16 ; 2) 
 
 
N=16 
-6.5  (3 ; -16) 
 
0.0001 
Time to ART initiation 
relative to HIV dx (days) 
(median, IQR) 
 
N=648 
13      (7 ; 38.5) 
 
N=100 
48   (26 ; 250.5) 
 
N=445 
12   (7 ; 28) 
 
N=97 
5   (3 ; 9) 
 
 
0.0001 
Time to ART initiation 
relative to hospital 
admission (days) 
(median, IQR) 
 
 
N=749 
7        (3 ; 11) 
 
 
N=127 
NA 
 
 
N=510 
8     (6 ; 13) 
 
 
N=106 
5   (3 ; 7) 
 
0.0001 
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*In table 1 non-normally distributed continuous variables were analysed using the Kruskal- Wallis non-parametric test. The Chi-squared test 
of association and Fisher’s Exact test were used to test associations between categorical variables. 
 
Table 2: Characteristics of caregivers of HIV-infected children prior to ART initiation 
 
*The Chi-squared test of association and Fisher’s Exact test were used to test associations between categorical variables. 
 
Table 3: Primary diagnosis of children on presentation to hospital 
 
 ICU  (N=106) GMWs  (N=509) 
Pneumonia 96 229 
Gastroenteritis 5 137 
Malnutrition 1 33 
Septicaemia 1 14 
PTB - 13 
EPTB 1 19 
Upper Airway Obstruction - 17 
Meningitis 1 11 
Non-accidental Injury - 4 
Surgical conditions 1 9 
Other Medical Conditions - 23 
 
 
 
 
 
 
 Overall Baseline Caregiver 
Characteristics   
Caregiver Characteristics Stratified According to ARV Initiation Location 
Outpatient HIV clinics General Medical Wards ICU P-value 
Reported Maternal HIV 
Status at ART initiation 
(%) 
Positive 
Negative 
Unknown 
 
 
N=749 
540   (72.1) 
46     (6.1) 
163   (21.8) 
 
 
N=127 
103   (81.1) 
4       (3.2) 
20     (15.8) 
 
 
N=509 
358   (70.3) 
32     (6.3) 
119   (23.4) 
 
 
N=106 
72   (67.9) 
10   (9.4) 
24   (22.6) 
 
 
0.1 
Maternal MTCT 
Prophylaxis (%) 
Yes 
No 
Unknown 
 
N=749 
258   (34.5) 
353   (47.1) 
138   (18.4) 
 
N=127 
43   (33.9) 
68   (53.5) 
16   (12.6) 
 
N=509 
164   (32.2) 
243   (47.7) 
102   (20.0) 
 
N=106 
46   (43.4) 
40   (37.7) 
20   (18.9) 
 
 
0.05 
Maternal ART at ART 
initiation (%) 
Yes 
No 
Unknown 
NA 
 
N=749 
98     (13.1) 
487   (65.0) 
118   (15.7) 
46     (6.1) 
 
N=127 
21     (16.5) 
85     (66.9) 
10     (7.9) 
11     (8.7) 
 
N=509 
67     (13.2) 
325   (63.9)    
94     (18.5) 
23     (4.5) 
 
N=106 
9     (8.5) 
70   (66.0) 
15   (14.2) 
12   (11.1) 
 
 
0.33 
 
Primary Caregiver Status 
(%) 
Mother 
Other 
None 
 
N=749 
647   (86.4) 
69     (9.2) 
33     (4.4) 
 
N=127 
104   (81.9) 
18     (14.2) 
5        (3.9) 
 
N=509 
435   (85.8) 
50     (9.9) 
24     (3.9) 
 
N=106 
101   (95.3) 
1       (0.9) 
4       (3.8) 
 
 
0.004 
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Table 4: CD4 percentage and viral load responses after 6 months of ART 
 
 
GMWs OHCs ICU  p-value 
CD4 percent at 6 months 
Number (%) with CD4 ≥25% 
Number (%) with CD4 <25% 
N=330 
158   (47.9%) 
172   (52.1%) 
 
N=99 
55   (55.6%) 
44   (44.4%) 
 
N=59 
36   (61.0%) 
23   (39.0%) 
 
0.1 
*CD4% change at 6 months  
Median percentage difference (IQR)  
N=320 
4.7  (0.7 ; 11.3) 
 
N=91 
3.2  (0.1 ; 9.2) 
N=54 
9.1  (4.9 ; 14.7) 
 
0.001 
Viral Load at 6 months 
Number (%) ≤50 copies/mL 
Number (%) ≤400 copies/mL 
N=280 
171   (61.1%) 
198   (70.7%) 
 
N=93 
69   (74.2%) 
75   (80.7%) 
N=51 
24   (47.1%) 
32   (62.8%) 
 
0.004 
0.05 
*Log10 viral load change at 6 months 
Median percentage difference (IQR) 
N=216 
 
-4.7  (2.9 ; 5.9) 
N=90 
 
-4.7  (3.8 ; 5.4) 
N=39 
 
-4.1  (1.5 ; 5.3) 
 
 
 
0.35 
 
*Analyses of the differences between 6 month and baseline CD4% or Log10 viral load values in children with paired specimen results. 
 
Figure 1: Kaplan-Meier estimates for outcomes of (a) mortality, n=742 and (b) attrition, 
n=742 at 6 months, according to ART initiation iocation 
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Table 5: Predictors of mortality during the first 6 months of ART 
 
 
* Number of counselling sessions received by caregiver prior to or during ART initiation. 
† Is there a second caregiver who is able to administer ART to the child in the event of the primary caregiver not being present. 
 
 
 
 
 
 
 
 
 
 
 
Univariate HR (95% CI) of 
Mortality 
P-value Adjusted HR (95% CI) of  
Mortality (N-700) 
P-value 
Age at ART initiation 
 
<3 months 
3 – 12 months 
13 – 60 months 
>60 months 
(N=749) 
 
1.8  (0.95 – 3.4) 
1.2  (0.7 – 2.1) 
0.5   (0.2 – 1.2) 
1 
 
 
0.07 
0.59 
0.12 
 
 
1.8  (0.9 – 3.4) 
1 
1 
1 
 
 
0.07 
 
WAZ categories 
 
Mild-normal 
Moderate malnutrition 
Severe malnutrition 
(N=700) 
 
1 
2.3  (1.1 – 4.8) 
2.5  (1.3 – 4.9) 
 
 
 
0.02 
0.008 
 
 
1 
2.4  (1.1– 5.2) 
3.2  (1.6 – 6.5) 
 
 
 
0.02 
0.001 
Number of Caregiver 
Counselling Sessions* 
 
0 
1 
2 
3 
(N=749) 
 
 
3.8  (1.9 – 7.6) 
2.7  (0.7 – 11.1) 
0.6  (0.1 – 4.1) 
1 
 
 
 
0.0001 
0.17 
0.58 
 
 
 
2.9 (1.4– 6.0) 
1 
1 
1 
 
 
 
0.005 
 
ART initiation location 
 
GMW 
OHC 
ICU 
(N=742) 
 
0.7  (0.4 – 1.2) 
1 
2.6  (1.4 – 4.9) 
 
 
0.144 
 
0.002 
 
 
1 
1 
2.6  (1.4 – 4.9) 
 
 
 
 
0.003 
Caregiver Support† 
 
Yes 
No 
Not Available 
(N=749) 
 
1 
1.0  (0.6 – 1.8) 
2.5  (1.2 – 5.2) 
 
 
 
0.95 
0.013 
 
 
1 
1 
2.4  (1.1  – 5.0) 
 
 
 
 
0.02 
Maternal ART at ART 
initiation   
 
Yes 
No 
Not Available 
NA 
(N=749) 
 
 
1.1  (0.5 – 2.5) 
0.5  (0.3 – 0.8) 
2.3  (1.3 – 4.3) 
1 
 
 
 
0.762 
0.011 
0.005 
 
 
 
1 
0.5   (0.3 – 0.9) 
1 
1 
 
 
 
 
0.02 
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Table 6: Predictors of attrition during the first 6 months of ART 
 
* Number of counselling sessions received by caregiver prior to or during ART initiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient Factor Univariate HR (95% CI) of 
Attrition 
P-value Adjusted HR (95% CI) of 
Attrition (N=700) 
P-value 
Age at ART initiation 
 
<3 months 
3 – 12 months 
13 – 60 months 
>60 months 
(N=749) 
 
1.3   (0.7 – 2.3) 
1.6   (0.97 – 2.5) 
0.5   (0.2 – 1.0) 
1 
 
 
0.4 
0.1 
0.1 
 
 
1 
1 
0.5   (0.2 – 1.1) 
1 
 
 
 
 
0.08 
WAZ categories 
 
Mild-normal 
Moderate malnutrition 
Severe malnutrition 
(N=700) 
 
1 
1.2  (0.7 -2.1) 
1.8  (1.1 – 2.9) 
 
 
 
0.53 
0.014 
 
 
1 
1 
1.8  (1.1 – 2.8) 
 
 
 
 
0.02 
Number of Caregiver 
Counselling Sessions* 
 
0 
1 
2 
3 
(N=749) 
 
 
3.1  (1.7 – 5.7) 
2.9  (0.9 – 9.3) 
1.2  (0.4 – 3.9) 
1 
 
 
 
0.0001 
0.07 
0.72 
 
 
 
2.6  (1.4 – 5.0) 
1 
1 
1 
 
 
 
0.003 
 
Maternal ART at ART 
initiation   
 
Yes 
No 
Not Available 
NA 
(N=749) 
 
 
1 
0.7  (0.4 – 1.0) 
1.9  (1.1 – 3.1) 
1 
 
 
 
 
0.07 
0.018 
 
 
 
1 
1 
1.6  (0.9 – 2.7) 
1 
 
 
 
 
0.08 
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Table 7: Predictors of an unsuppressed viral load after 6 months of ART: (a) predictors of 
viral load > 50 copies/mL and (b) predictors of viral load >400 copies/mL  
 
* Is there a second caregiver who is able to administer ART to the child in the event of the primary caregiver not being present. 
 
 
 
 
 
 
 
 
(a)  
 
 
Univariate OR (95% CI)  P-value Adjusted OR (95% CI) (N=338) P-value 
Age at ART initiation 
 
<3 months 
3 – 12 months 
13 – 60 months 
>60 months 
(N=429) 
 
1.6  (0.95  – 2.7) 
2.4  (1.6 – 3.5) 
0.6   (0.4 – 0.9) 
1 
 
 
0.078 
0.001 
0.029 
 
 
3.1  (1.8 – 5.3) 
2.6  (1.3 – 4.9) 
1 
1 
 
 
0.001 
0.005 
Caregiver Support* 
 
Yes 
No 
Not Available 
(N=429) 
 
1 
0.6  (0.4 – 0.97) 
0.7  (0.3 – 1.4) 
 
 
 
0.039 
0.298 
 
 
1 
0.5  (0.3 – 0.9) 
1 
 
 
 
0.013 
 
Maternal ART at ART 
initiation 
 
Yes 
No 
Not Available 
NA 
(N=429) 
 
 
0.8    (0.5 – 1.4) 
1.7  (1.1 – 2.7) 
0.4  (0.2 – 0.8) 
1 
 
 
 
0.433 
0.012 
0.009 
 
 
 
1 
1 
0.4  (0.2 – 0.8) 
1 
 
 
 
 
 
0.011 
(b) 
 Univariate OR (95% CI)  P-value Adjusted OR (95% CI) (N=338) P-value 
Age at ART initiation 
 
<3 months 
3 – 12 months 
13 – 60 months 
>60 months 
(N=429) 
 
1.9  (1.1 – 3.3) 
1.7  (1.1 – 2.7) 
0.6   (0.4 – 1.1) 
1 
 
 
0.018 
0.01 
0.12 
 
 
2.95  (1.5 – 5.9) 
2.6  (1.4 – 4.6) 
1 
1 
 
 
0.002 
0.002 
 
Caregiver Support* 
 
Yes 
No 
Not Available 
(N=429) 
 
1 
0.6  (0.4 – 0.97) 
1.0  (0.5 – 2.3) 
 
 
 
0.039 
0.871 
 
 
1 
0.5  (0.3 – 0.9) 
1 
 
 
 
0.017 
 
Reported Maternal HIV 
Status at ART initiation 
Negative 
Positive 
Not Available 
(N=429) 
 
 
 
1 
1.8  (1.1 – 3.1) 
0.4  (0.2 – 0.7) 
 
 
 
 
 
 
0.024 
0.005 
 
 
 
 
1 
1 
0.3  (0.1 – 0.6) 
 
 
 
 
 
 
0.002 
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PART D: APPENDICES 
 
  1) DATA CAPTURE FORM 
DATA  CAPTURE SHEET 
 
 
 
Patient Folder Number 
Date of Birth 
Gender 
 
 
 
ADMISSION DETAILS 
 
Date of admission  
Date of discharge  
Ward ICU General Wards OPD 
Length of stay in general ward (days)  
If admitted to ICU: 
Date of ICU admission  
Indication for ICU admission  
Length of stay in ICU     (days)  
Ventilation Yes No 
If yes, mode of ventilation CPAP IPPV HFOV 
Mortality (in hospital) Yes No 
If yes, date of death  
Cause of death  
 
PATIENT BASELINE FACTORS 
 
HIV diagnosis Date  Site  
ARV initiation site ICU General Wards OPD 
ARV start date: 
Age (years): 
CD4 count: CD4 %: 
Viral Load: 
Stage 1 2 3 4 
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Weight (kg): Height (cm): 
 
Baseline co-
morbidity 
 
Primary diagnosis 
 
 
 
 
 
 
Secondary diagnosis 
 
 
 
 
 
 
TB co-morbidity 
Yes No 
Definite Probable 
Site of disease  
 
Complicated Uncomplicated TB Meningitis 
 Date of treatment initiation  
 
MATERNAL/CAREGIVER FACTORS (at ARV initiation) 
 
Age (years): 
Relationship to child  
Literate Yes No 
Maternal history 
HIV status Positive Negative Unknown 
ARV treatment Yes No 
MTCT drugs None NVP AZT/NVP HAART 
 
SOCIAL FACTORS 
 
Household Disclosure Yes No 
Housing Formal Informal 
Support Yes No 
Income Yes R No 
 
ARV DRUG REGIMEN  
 
Stavudine Abacavir Lamivudine 
Lopinavir/Ritonavir Efavirenz Ritonavir 
    Other: 
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CAREGIVER COUSELLING SESSIONS 
 
1. 
 
2. 3. 
 
6 MONTH OUTCOMES 
 
CD4 count: CD4 %: 
Viral Load: 
Weight (kg): Height (cm): 
Loss to Follow-Up Yes No 
If yes, date of last visit 
Discontinued Treatment Yes No 
If yes, date treatment stopped 
Mortality Yes No 
If yes, date of death 
Transferred Out Yes No 
If yes, date of transfer 
If yes, health care facility transferred out to 
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2) ETHICAL APPROVAL FROM THE UNIVERSITY OF CAPE TOWN FACULTY 
OF HEALTH SCIENCES RESEARCH ETHICS COMMITTEE 
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3) SAMJ AUTHOR GUIDELINES  
 
 Author Guidelines 
Accepted manuscripts that are not in the correct format specified in these 
guidelines will be returned to the author(s) for correction, and will delay 
publication. 
 
AUTHORSHIP 
Named authors must consent to publication. Authorship should be based on: (i) substantial 
contribution to conception, design, analysis and interpretation of data; (ii) drafting or critical 
revision for important intellectual content; or (iii) approval of the version to be published. 
These conditions must all be met (uniform requirements for manuscripts submitted to 
biomedical journals; refer to www.icmje.org). 
 
CONFLICT OF INTEREST 
Authors must declare all sources of support for the research and any association with a 
product or subject that may constitute conflict of interest. 
 
RESEARCH ETHICS COMMITTEE APPROVAL 
Provide evidence of Research Ethics Committee approval of the research where relevant. 
 
PROTECTION OF PATIENT'S RIGHTS TO PRIVACY 
Identifying information should not be published in written descriptions, photographs, and 
pedigrees unless the information is essential for scientific purposes and the patient (or 
parent or guardian) gives informed written consent for publication. The patient should be 
shown the manuscript to be published. Refer to www.icmje.org. 
 
ETHNIC CLASSIFICATION 
References to ethnic classification must indicate the rationale for this. 
 
MANUSCRIPTS 
Shorter items are more likely to be accepted for publication, owing to space constraints and 
reader preferences. 
Research articles (previously 'Original articles') not exceeding 3 000 words, with up to 6 
tables or illustrations, are usually observations or research of relevance to clinical medicine 
and related fields. References should be limited to no more than 15. Please provide a 
structured abstract not exceeding 250 words, with the following recommended headings: 
Background, Objectives, Methods, Results, and Conclusion. 
Scientific letters will be considered for publication as shorter Research articles.  
Editorials, Opinions, etc. should be about 1000 words and are welcome, but unless invited, 
will be subjected to the SAMJ peer review process. 
Review articles are rarely accepted unless invited. 
Letters to the editor, for publication, should be about 400 words with only one illustration 
or table, and must include a correspondence address. 
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Forum articles must be accompanied by a short description (50 words) of the affiliation 
details/interests of the author(s). Refer to recent forum articles for guidance. Please provide 
an accompanying abstract not exceeding 150 words. 
Book reviews should be about 400 words and must be accompanied by the publication 
details of the book. 
Obituaries should be about 400 words and may be accompanied by a photograph. 
Guidelines must be endorsed by an appropriate body prior to consideration and all conflicts 
of interest expressed. A structured abstract not exceeding 250 words (recommended sub-
headings: Background, Recommendations, Conclusion) is required. Sections and sub-
sections must be numbered consecutively (e.g. 1. Introduction; 1.1 Definitions; 2. etc.) and 
summarised in a Table of Contents. References, appendices, figures and tables must be kept 
to a minumum. 
Guidelines exceeding 8 000 words will only be considered for publication as a supplement to 
the SAMJ; the costs of which must be covered by sponsorship or advertising. The Editor 
reserves the right to determine the scheduling of supplements. Understandably, a delay in 
publication must be anticipated dependent upon editorial workflow. 
  
MANUSCRIPT PREPARATION 
Refer to articles in recent issues for the presentation of headings and subheadings. If in 
doubt, refer to 'uniform requirements' - www.icmje.org. Manuscripts must be provided in 
UK English. 
Qualification, affiliation and contact details of ALL authors must be provided in the 
manuscript and in the online submission process. 
Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 
'intravenous (IV)' or 'Department of Health (DoH)'. 
Scientific measurements must be expressed in SI units except: blood pressure (mmHg) 
and haemoglobin (g/dl). Litres is denoted with a lowercase 'l' e.g. 'ml' for millilitres). Units 
should be preceded by a space (except for %), e.g. '40 kg' and '20 cm' but '50%'. 
Greater/smaller than signs (> and 40 years of age'. The same applies to ± and º, i.e. '35±6' 
and '19ºC'. 
Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160... 
Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' Round 
brackets (parentheses) should be used, as opposed to square brackets, which are reserved 
for denoting concentrations or insertions in direct quotes. 
General formatting The manuscript must be in Microsoft Word or RTF document format. 
Text must be single-spaced, in 12-point Times New Roman font, and contain no 
unnecessary formatting (such as text in boxes, with the exception of Tables). 
 
ILLUSTRATIONS AND TABLES 
If tables or illustrations submitted have been published elsewhere, the author(s) should 
provide consent to republication obtained from the copyright holder. 
Tables may be embedded in the manuscript file or provided as 'supplementary files'. 
They must be numbered in Arabic numerals (1,2,3...) and referred to consecutively in the 
text (e.g. 'Table 1'). Tables should be constructed carefully and simply for intelligible data 
representation. Unnecessarily complicated tables are strongly discouraged. Tables must be 
cell-based (i.e. not constructed with text boxes or tabs), and accompanied by a concise title 
and column headings. Footnotes must be indicated with consecutive use of the following 
symbols: * † ‡ § ¶ || then ** †† ‡‡ etc. 
Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. 
Figure legends: Fig. 1. 'Title...' All illustrations/figures/graphs must be of high 
resolution/quality: 300 dpi or more is preferable, but images must not be resized to 
increase resolution. Unformatted and uncompressed images must be attached individually 
as 'supplementary files' upon submission (not solely embedded in the accompanying 
manuscript). TIFF and PNG formats are preferable; JPEG and PDF formats are accepted, but 
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authors must be wary of image compression. Illustrations and graphs prepared in Microsoft 
Powerpoint or Excel must be accompanied by the original workbook. 
 
REFERENCES 
References must be kept to a maximum of 15. Authors must verify references from 
original sources. Only complete, correctly formatted reference lists will be accepted. 
Reference lists must be generated manually and not with the use of reference manager 
software. Citations should be inserted in the text as superscript numbers between square 
brackets, e.g. These regulations are endorsed by the World Health Organization,[2] and 
others.[3,4-6] All references should be listed at the end of the article in numerical order of 
appearance in the Vancouver style (not alphabetical order). Approved abbreviations of 
journal titles must be used; see the List of Journals in Index Medicus. Names and initials of 
all authors should be given; if there are more than six authors, the first three names should 
be given followed by et al. First and last page, volume and issue numbers should be given. 
Wherever possible, references must be accompanied by a digital object identifier 
(DOI) link and PubMed ID (PMID)/PubMed Central ID (PMCID). Authors are 
encouraged to use the DOI lookup service offered by CrossRef. 
Journal references: Price NC, Jacobs NN, Roberts DA, et al. Importance of asking about 
glaucoma. Stat Med 1998;289(1):350-355. [http://dx.doi.org/10.1000/hgjr.182] [PMID: 
2764753] 
Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth, 
1975:96-101. Chapter/section in a book: Weinstein L, Swartz MN. Pathogenic Properties of 
Invading Microorganisms. In: Sodeman WA jun, Sodeman WA, eds. Pathologic Physiology: 
Mechanisms of Disease. Philadelphia: WB Saunders, 1974:457-472. 
Internet references: World Health Organization. The World Health Report 2002 - Reducing 
Risks, Promoting Healthy Life. Geneva: World Health Organization, 2002. 
http://www.who.int/whr/2002 (accessed 16 January 2010). 
Other references (e.g. reports) should follow the same format: Author(s). Title. Publisher 
place: publisher name, year; pages. Cited manuscripts that have been accepted but not yet 
published can be included as references followed by '(in press)'. Unpublished observations 
and personal communications in the text must not appear in the reference list. The full 
name of the source person must be provided for personal communications e.g. '...(Prof. 
Michael Jones, personal communication)'. 
 
PROOFS  
A PDF proof of an article may be sent to the corresponding author before publication to 
resolve remaining queries. At that stage, only typographical changes are permitted; the 
corresponding author is required, having conferred with his/her co-authors, to reply within 2 
working days in order for the article to be published in the issue for which it has been 
scheduled. 
 
CHANGES OF ADDRESS 
Please notify the Editorial Department of any contact detail changes, including email, to 
facilitate communication. 
 
CPD POINTS 
Authors can earn up to 15 CPD CEUs for published articles. Certificates may be requested 
after publication of the article. 
 
CHARGES 
There is no charge for the publication of manuscripts. 
Please refer to the section on 'Guidelines' regarding the publication of supplements, where a 
charge may be applicable. 
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 Submission Preparation Checklist 
As part of the submission process, authors are required to check off their submission's 
compliance with all of the following items, and submissions may be returned to authors that 
do not adhere to these guidelines. 
1. Named authors consent to publication and meet the requirements of authorship as set 
out by the journal. 
2. The submission has not been previously published, nor is it before another journal for 
consideration. 
3. The text complies with the stylistic and bibliographic requirements in Author 
Guidelines. 
4. The manuscript is in Microsoft Word or RTF document format. The text is single-
spaced, in 12-point Times New Roman font, and contains no unnecessary formatting. 
5. Illustrations/figures are high resolution/quality (not compressed) and in an acceptable 
format (preferably TIFF or PNG). These must be submitted individually as 
'supplementary files' (not solely embedded in the manuscript). 
6. For illustrations/figures or tables that have been published elsewhere, the author has 
obtained written consent to republication from the copyright holder. 
7. Where possible, references are accompanied by a digital object identifier (DOI) and 
PubMed ID (PMID)/PubMed Central ID (PMCID). 
8. An abstract has been included where applicable. 
9. The research was approved by a Research Ethics Committee (if applicable) 
10. Any conflict of interest (or competing interests) is indicated by the author(s). 
  
 Copyright Notice 
The South African Medical Journal (SAMJ) reserves copyright of the material published. The 
work is licensed under a Creative Commons Attribution - Noncommercial Works License. 
Material submitted for publication in the SAMJ is accepted provided it has not been 
published or submitted for publication elsewhere. The SAMJ does not hold itself responsible 
for statements made by the authors. 
  
 Privacy Statement 
The SAMJ is committed to protecting the privacy of the users of this journal website. The 
names, personal particulars and email addresses entered in this website will be used only 
for the stated purposes of this journal and will not be made available to third parties without 
the user’s permission or due process. Users consent to receive communication from the 
SAMJ for the stated purposes of the journal. Queries with regard to privacy may be directed 
to publishing@hmpg.co.za. 
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